MCID: EPL164
MIFTS: 72

Epilepsy

Categories: Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Epilepsy

MalaCards integrated aliases for Epilepsy:

Name: Epilepsy 12 77 55 30 56 6 44 3 45 15 64 41 17 74
Epileptic Syndrome 12
Epilepsy Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1826
ICD9CM 36 345.9
MeSH 45 D004827
NCIt 51 C3020
SNOMED-CT 69 84757009
UMLS 74 C0014544

Summaries for Epilepsy

NINDS : 55 The epilepsies are a spectrum of brain disorders ranging from severe, life-threatening and disabling, to ones that are much more benign. In epilepsy, the normal pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness. The epilepsies have many possible causes and there are several types of seizures. Anything that disturbs the normal pattern of neuron activity—from illness to brain damage to abnormal brain development—can lead to seizures. Epilepsy may develop because of an abnormality in brain wiring, an imbalance of nerve signaling chemicals called neurotransmitters, changes in important features of brain cells called channels, or some combination of these and other factors. Having a single seizure as the result of a high fever (called febrile seizure) or head injury does not necessarily mean that a person has epilepsy. Only when a person has had two or more seizures is he or she considered to have epilepsy. A measurement of electrical activity in the brain and brain scans such as magnetic resonance imaging or computed tomography are common diagnostic tests for epilepsy.

MalaCards based summary : Epilepsy, also known as epileptic syndrome, is related to epilepsy, idiopathic generalized 10 and childhood absence epilepsy, and has symptoms including seizures, tremor and back pain. An important gene associated with Epilepsy is SLC2A1 (Solute Carrier Family 2 Member 1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Transmission across Chemical Synapses. The drugs Clobazam and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include temporal lobe, brain and testes, and related phenotypes are no effect and behavior/neurological

Disease Ontology : 12 A brain disease that is characterized by the occurrance of at least two unprovoked seizures resulting from a persistent epileptogenic abnormality of the brain that is able to spontaneously generate paroxysmal activity and typically manifested by sudden brief episodes of altered or diminished consciousness, involuntary movements, or convulsions.

MedlinePlus : 44 Epilepsy is a brain disorder that causes people to have recurring seizures. The seizures happen when clusters of nerve cells, or neurons, in the brain send out the wrong signals. People may have strange sensations and emotions or behave strangely. They may have violent muscle spasms or lose consciousness. Epilepsy has many possible causes, including illness, brain injury, and abnormal brain development. In many cases, the cause is unknown. Doctors use brain scans and other tests to diagnose epilepsy. It is important to start treatment right away. There is no cure for epilepsy, but medicines can control seizures for most people. When medicines are not working well, surgery or implanted devices such as vagus nerve stimulators may help. Special diets can help some children with epilepsy. NIH: National Institute of Neurological Disorders and Stroke

PubMed Health : 64 About epilepsy: In epilepsy, certain areas of the brain or all areas of the brain are overactive, sending too many signals. This results in seizures, sometimes also referred to as epileptic fits. Epileptic seizures can take different forms. They may cause only a few muscles to twitch, for instance, or they may cause your whole body to convulse (shake uncontrollably) and lead to loss of consciousness.Epilepsy can arise at any age. Some people have their first seizure in childhood, and others have their first seizure in older age. There are usually no physical symptoms in between seizures. But the constant fear of having another seizure may affect your work and private life.Medication can help to prevent seizures and maintain a good quality of life. Unfortunately, medication doesn't always help, though: About 3 out of 10 people still have regular seizures. This makes it particularly difficult for them to live with the condition.

Wikipedia : 77 Epilepsy is a group of neurological disorders characterized by epileptic seizures. Epileptic seizures... more...

Related Diseases for Epilepsy

Diseases in the Epilepsy family:

Benign Familial Infantile Epilepsy Depdc5-Related Epilepsy
Kcnt1-Related Epilepsy

Diseases related to Epilepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1496)
# Related Disease Score Top Affiliating Genes
1 epilepsy, idiopathic generalized 10 35.0 CACNB4 CHRNA4 EFHC1 GABRA1 GABRB3 GABRG2
2 childhood absence epilepsy 34.6 CHRNA4 EFHC1 GABRA1 GABRB3 GABRG2 SCN1B
3 epilepsy, idiopathic generalized 34.6 CACNB4 CHRNA4 CHRNB2 EFHC1 GABRA1 GABRG2
4 benign epilepsy with centrotemporal spikes 34.6 EPM2A GABRG2 RELN SCN1B SLC2A1
5 epilepsy, nocturnal frontal lobe, 1 34.6 CHRNA2 CHRNA4 CHRNB2 GABRG2 SCN1A SCN1B
6 generalized epilepsy with febrile seizures plus 34.5 GABRG2 SCN1A SCN1B SCN8A
7 temporal lobe epilepsy 34.5 LGI1 RELN SCN1B
8 autosomal dominant nocturnal frontal lobe epilepsy 34.5 CHRNA2 CHRNA4 CHRNB2
9 focal epilepsy 34.4 CHRNA2 CHRNA4 CHRNB2 GABRG2 LGI1 SCN1A
10 epilepsy, myoclonic juvenile 34.4 CACNB4 EFHC1
11 benign familial infantile epilepsy 34.4 CHRNA2 SCN1B SCN8A
12 epilepsy, nocturnal frontal lobe, 3 34.3 CHRNA4 CHRNB2
13 generalized epilepsy with febrile seizures plus, type 1 34.3 SCN1A SCN1B
14 epileptic encephalopathy, early infantile, 6 34.2 GABRA1 GABRB3 GABRG2 SCN1A SCN1B SCN8A
15 juvenile absence epilepsy 34.2 EFHC1 GABRA1
16 early myoclonic encephalopathy 34.1 EPM2A GABRG2 SCN1A SCN1B
17 unverricht-lundborg syndrome 34.1 EFHC1 EPM2A NHLRC1
18 myoclonic epilepsy of infancy 34.1 GABRG2 SCN1A SCN8A
19 autosomal dominant epilepsy with auditory features 34.0 LGI1 RELN
20 autosomal dominant nocturnal frontal lobe epilepsy 2 34.0 CHRNA4 CHRNB2
21 epilepsy, familial temporal lobe, 1 34.0 LGI1 RELN
22 epilepsy with generalized tonic-clonic seizures 33.9 EFHC1 SCN1A
23 early onset absence epilepsy 33.8 CHRNB2 SCN1B SLC2A1
24 seizures, benign familial infantile, 3 33.8 CHRNA4 GABRG2 SCN1A SCN1B
25 myoclonus epilepsy 33.6 EPM2A NHLRC1
26 mental retardation, x-linked, syndromic, hedera type 33.3 GABRA1 LGI1
27 lennox-gastaut syndrome 33.3 GABRA1 GABRB3 GABRG2 SCN1A SLC2A1
28 visual epilepsy 33.2 ATP1A3 CLN8 SCN1A SLC2A1
29 myoclonus 32.9 EPM2A NHLRC1 SLC2A1
30 febrile seizures 31.9 CHRNA4 CHRNB2 GABRG2 SCN1A SCN1B
31 alacrima, achalasia, and mental retardation syndrome 31.1 OTUD6B SCN1A SLC2A1
32 hemiplegia 30.8 ATP1A3 SCN1A SLC2A1
33 psychotic disorder 30.6 GABRA1 GABRB3 RELN
34 hemiplegic migraine 30.2 ATP1A3 SCN1A SLC2A1
35 myoclonic epilepsy of lafora 12.5
36 epilepsy, pyridoxine-dependent 12.5
37 myoclonic epilepsy of unverricht and lundborg 12.5
38 ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant 12.5
39 epilepsy, focal, with speech disorder and with or without mental retardation 12.4
40 epilepsy, familial focal, with variable foci 1 12.4
41 centralopathic epilepsy 12.4
42 epilepsy, progressive myoclonic, 3, with or without intracellular inclusions 12.4
43 epilepsy, idiopathic generalized 13 12.4
44 epilepsy-aphasia spectrum 12.4
45 epilepsy, idiopathic generalized 11 12.4
46 epilepsy, progressive myoclonic 7 12.4
47 photosensitive epilepsy 12.4
48 myoclonic epilepsy, familial infantile 12.4
49 epilepsy, progressive myoclonic, 6 12.4
50 epilepsy, progressive myoclonic, 8 12.4

Graphical network of the top 20 diseases related to Epilepsy:



Diseases related to Epilepsy

Symptoms & Phenotypes for Epilepsy

UMLS symptoms related to Epilepsy:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, non-epileptic convulsion

GenomeRNAi Phenotypes related to Epilepsy according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ATP1A3 CACNB4 CHRNA2 CHRNA4 CHRNB2 CLN8

MGI Mouse Phenotypes related to Epilepsy:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 ATP1A3 CACNB4 CHRNA4 CHRNB2 CLN8 EFHC1
2 growth/size/body region MP:0005378 10.28 ATP1A3 CACNB4 CHRNB2 EPM2A GABRA1 GABRB3
3 mortality/aging MP:0010768 10.25 ATP1A3 CACNB4 CHRNA4 CHRNB2 CLN8 EPM2A
4 nervous system MP:0003631 10.13 ATP1A3 CACNB4 CHRNA2 CHRNA4 CHRNB2 CLN8
5 muscle MP:0005369 9.91 ATP1A3 CACNB4 CHRNB2 EFHC1 EPM2A GABRA1
6 hearing/vestibular/ear MP:0005377 9.85 CACNB4 CHRNB2 GABRA1 GABRB3 SCN8A TSHR
7 reproductive system MP:0005389 9.61 CACNB4 CLN8 GABRA1 GABRB3 GABRG2 RELN
8 vision/eye MP:0005391 9.23 CACNB4 CHRNB2 CLN8 LGI1 RELN SCN1B

Drugs & Therapeutics for Epilepsy

PubMedHealth treatment related to Epilepsy: 64

The most suitable kind of treatment for a specific person will depend on the type of epilepsy they have and the course of their disease so far. Epilepsy is usually treated with medication known as anti-epileptic drugs (AEDs). These include various medications from different groups of drugs. If a certain medication doesn’t work when a low dose is used, the dose can be increased. If it still doesn’t work, a medication from a different group of drugs can be tried out or several medications can be used together.Seizures are often one-off events so no treatment is needed at first. People usually only start treatment if they have a second seizure. But certain people, for instance those with a brain disease, are more likely to have further seizures. In those cases it might be a good idea to start treatment after the first seizure. This will greatly depend on the person’s individual situation. It is important to discuss all the options with your doctor.People who decide to take medication usually take it for many years. Some people can try to stop taking medication after a while if they have not had any seizures for several years. Others have to take medication for the rest of their lives.If seizures can’t be prevented with medication, a surgical procedure may be considered. The options include:Brain surgery: If someone has partial seizures and it is clear which part of the brain is triggering them, that part of the brain can be surgically removed. But this is not always possible.Vagus nerve stimulation: In this procedure, a pacemaker-like device is implanted under the skin of your chest, where it produces electrical signals. It is connected to the vagus nerve in your neck and is meant to prevent the nerve cells from being too active.The treatment is overseen by a neurologist. Children and teenagers with epilepsy will see a pediatric neurologist. Some of the diagnostic tests and treatments are often carried out in a hospital. There are outpatient facilities and clinics that specialize in treatments for people with epilepsy (e.g. epilepsy centers, specialized hospital departments or doctors’ practices). These are particularly suitable if you have a specific problem, if the diagnosis is not clear, or if you keep on having seizures despite treatment.When people with epilepsy have seizures they do not usually need treatment. The most important thing that helpers can do is stay calm and prevent injury. If the seizure lasts longer than five minutes or if several seizures occur within a short space of time, the emergency services should be informed (e.g. by calling 112 in Germany and most European countries, or 911 in the U.S.). Severe epileptic seizures may require a hospital stay.

Drugs for Epilepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 623)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobazam Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 22316-47-8 2789
2
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
4
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
5
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
6
Clonazepam Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 1622-61-3 2802
7
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84057-84-1 3878
8
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99-66-1 3121
9
Tiagabine Approved, Investigational Phase 4,Phase 1 115103-54-3 60648
10
Felbamate Approved Phase 4 25451-15-4 3331
11
Levetiracetam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 102767-28-2 441341
12
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 97240-79-4 5284627
13
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 298-46-4 2554
14
Ethosuximide Approved Phase 4,Phase 3 77-67-8 3291
15
Rufinamide Approved Phase 4,Phase 3 106308-44-5 129228
16
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Phase 3 59-66-5 1986
17
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60142-96-3 3446
18
Phenytoin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-41-0 1775
19
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
20
Oxcarbazepine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28721-07-5 34312
21
Vigabatrin Approved Phase 4,Phase 3,Phase 2,Not Applicable 68506-86-5, 60643-86-9 5665
22
Zonisamide Approved, Investigational Phase 4,Phase 3,Not Applicable 68291-97-4 5734
23
Nitrazepam Approved Phase 4,Phase 2 146-22-5 4506
24
Phenobarbital Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-06-6 4763
25
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
26
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 2078-54-8 4943
27
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
28
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 439-14-5 3016
29
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
30
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 846-49-1 3958
31
Atropine Approved, Vet_approved Phase 4,Not Applicable 5908-99-6, 51-55-8 174174
32
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
33
Biperiden Approved, Investigational Phase 4,Phase 3 514-65-8 2381
34
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
35
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
36
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
37
Lacosamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 860352-01-8, 175481-36-4 219078
38
Eslicarbazepine acetate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 236395-14-5, 75970-99-9 123618
39
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2 1197-18-8 5526
40
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 159351-69-6 70789204 6442177
41
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
42
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 5284616 6436030
43
Amitriptyline Approved Phase 4,Phase 3 50-48-6 2160
44
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
45
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
46
Levonorgestrel Approved, Investigational Phase 4,Phase 1 797-63-7, 17489-40-6 13109
47
Citalopram Approved Phase 4,Not Applicable 59729-33-8 2771
48
Tocopherol Approved, Investigational Phase 4,Early Phase 1 1406-66-2 14986
49
Hydralazine Approved Phase 4 86-54-4 3637
50
Clevidipine Approved, Investigational Phase 4 167221-71-8

Interventional clinical trials:

(show top 50) (show all 1743)
# Name Status NCT ID Phase Drugs
1 Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy Unknown status NCT02726919 Phase 4 Clobazam
2 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
3 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
4 Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy Unknown status NCT01932502 Phase 4 clobazam (Onfi);Initial conversion and titration;Conversion schedule - Week 1;Conversion schedule - Week 2;Conversion schedule - Week 3
5 Hormone Profiles in Adults With Newly Diagnosed Epilepsy Unknown status NCT00137709 Phase 4 Sodium valproate;Lamotrigine
6 Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy Unknown status NCT00552526 Phase 4 Antiepileptic drug (AED)
7 Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy Unknown status NCT02900755 Phase 4 Perampanel
8 Study to Improve the Treatment of Epilepsy (SITE) Unknown status NCT00133081 Phase 4 All registered antiepileptic drugs
9 Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote Unknown status NCT00312676 Phase 4
10 A Trial of Generic Substitution of Antiepileptic Drugs Unknown status NCT02429596 Phase 4 Experimental
11 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients Unknown status NCT00132223 Phase 4 Contrast agent
12 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4 levetiracetam
13 Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects Unknown status NCT01370486 Phase 4 melatonin;placebo
14 Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates Unknown status NCT02645279 Phase 4 IV midazolam
15 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
16 Efficacy of Levetiracetam in Control of Neonatal Seizures Guided by an EEG Unknown status NCT03107507 Phase 4 Levetiracetam;Phenobarbital
17 Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases Unknown status NCT00796380 Phase 4 Xingnaojing
18 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
19 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
20 Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients Unknown status NCT03004209 Phase 4 Erythropoietin
21 Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability Unknown status NCT02078336 Phase 4 Midazolam Mylan;Lorazepam Mylan;Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
22 Preventive Treatment of Episodic and Chronic Migraine Unknown status NCT01319825 Phase 4 milnacipran
23 Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies Completed NCT00896987 Phase 4 lamotrigine (Lamictal);Carbamazepine (Tegretol)
24 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study) Completed NCT01733394 Phase 4 Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand";lamotrigine
25 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design Completed NCT01713777 Phase 4 Lamotrigine Generic "A";Lamotrigine generic "B"
26 Standardized Educational Plan for Epilepsy Patients With Comorbidities Completed NCT01804322 Phase 4
27 Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study Completed NCT02100644 Phase 4 Lamotrigine tablets 25/100 mg
28 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy Completed NCT03052998 Phase 4 Ivermectin
29 Methylphenidate Treatment of Attention Deficits in Epilepsy Completed NCT02178995 Phase 4 Methylphenidate
30 Characterization of Epilepsy Patients BEEP 2b Completed NCT02707965 Phase 4 Oxcarbmazepine (brand name vs generic drugs);Divalproex Sodium (brand name vs generic drugs);Carbamazepine (brand name vs generic drugs);Lamotrigine (brand name vs generic drugs);levetiracetam (brand name vs generic drugs);Topiramate (brand name vs generic drugs);Zonisamide (brand name vs generic drugs);Phenytoin sodium (brand name vs generic drugs)
31 Cognitive and Behavioral Effects of Lacosamide Completed NCT01175954 Phase 4 Lacosamide;Lacosamide
32 RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy Completed NCT00564915 Phase 4
33 Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users Completed NCT02362373 Phase 4 levonorgestrel IUS
34 Levetiracetam for Benign Rolandic Epilepsy Completed NCT00181116 Phase 4 Levetiracetam
35 Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy Completed NCT01140867 Phase 4 zonisamide
36 A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy Completed NCT01689649 Phase 4 Topiramate
37 Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy Completed NCT00216567 Phase 4 topamax
38 Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy Completed NCT01190098 Phase 4 Lacosamide;Placebo
39 Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy. Completed NCT00245713 Phase 4 levetiracetam
40 Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy Completed NCT00043914 Phase 4 lamotrigine
41 Effect of Three Different Doses of Oral Cholecalciferol on 25-Hydroxyvitamin D Changes Among Epilepsy Patients With Hypovitaminosis D Completed NCT02890823 Phase 4 Cholecalciferol
42 S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy Completed NCT00630968 Phase 4 Levetiracetam (Keppra)
43 Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy Completed NCT01498822 Phase 4 Levetiracetam;Oxcarbazepine
44 Study of Valproate in Young Patients Suffering From Epilepsy Completed NCT00385411 Phase 4 valproate microgranules
45 Switchability Study Between Brand and Generic Topiramate Completed NCT02113787 Phase 4
46 Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy Completed NCT00160654 Phase 4 Levetiracetam
47 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
48 Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures Completed NCT00955357 Phase 4 Lacosamide
49 Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy Completed NCT00323947 Phase 4 Extended Release Methylphenidate (OROS-Methylphenidate)
50 A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy Completed NCT00266604 Phase 4 Topiramate

Search NIH Clinical Center for Epilepsy

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: epilepsy

Genetic Tests for Epilepsy

Genetic tests related to Epilepsy:

# Genetic test Affiliating Genes
1 Epilepsy 30

Anatomical Context for Epilepsy

MalaCards organs/tissues related to Epilepsy:

42
Temporal Lobe, Brain, Testes, Cortex, Heart, Bone, Amygdala

Publications for Epilepsy

Articles related to Epilepsy:

(show top 50) (show all 14693)
# Title Authors Year
1
Akinetopsia with achromatopsia due to focal epilepsy. ( 30856459 )
2019
2
Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis. ( 30730236 )
2019
3
A Comparison Among the Prevalence of Alexithymia in Patients With Psychogenic Nonepileptic Seizures, Epilepsy, and the Healthy Population: A Systematic Review of the Literature. ( 30876655 )
2019
4
The Relationship Between Epilepsy and Anxiety Disorders. ( 31037466 )
2019
5
Alteration of GABAergic signaling is associated with anxiety-like behavior in temporal lobe epilepsy mice. ( 30951784 )
2019
6
Psychometric properties of the Polish version of the Hamilton Anxiety Rating Scale in patients with epilepsy with and without comorbid anxiety disorder. ( 30884410 )
2019
7
Frontal lobe dysfunction as a predictor of depression and anxiety following temporal lobe epilepsy surgery. ( 30909053 )
2019
8
Mood, anxiety, and perceived quality of life in adults with epilepsy and intellectual disability. ( 30820944 )
2019
9
Psychometric properties and diagnostic utility of the State-Trait Anxiety Inventory in epilepsy with and without comorbid anxiety disorder. ( 30690323 )
2019
10
Cortisol and trait anxiety as relevant factors involved in memory performance in people with drug-resistant epilepsy. ( 30658320 )
2019
11
Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A) and The State-Trait Anxiety Inventory (STAI) accuracy for anxiety disorders detection in drug-resistant mesial temporal lobe epilepsy patients. ( 30599368 )
2019
12
Volume-Staged CyberKnife Stereotactic Radiosurgery for Treatment of Drug Resistant Epilepsy for a Spetzler-Martin Grade V Arteriovenous Malformation: A Case Report and Review of the Literature. ( 30797935 )
2019
13
Autism spectrum disorder and attention-deficit/hyperactivity disorder-related symptoms in benign childhood epilepsy with centrotemporal spikes: A prospective case-control study. ( 31026784 )
2019
14
Pharmacological treatment of attention-deficit/hyperactivity disorder in children and adolescents with epilepsy. ( 30665686 )
2019
15
Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy. ( 30682219 )
2019
16
Identification of a de novo FOXP1 mutation and incidental discovery of inherited genetic variants contributing to a case of autism spectrum disorder and epilepsy. ( 31111659 )
2019
17
High-functioning autism spectrum disorder with fluent speech and late-onset epilepsy: an unusual presentation of Inv-Dup (15) syndrome. ( 30991884 )
2019
18
Association of temporal lobe epilepsy with gambling disorder in a patient with mild intellectual disability and autism spectrum disorder. ( 30953956 )
2019
19
Recovery from Autism after Successful Surgery for a Benign Brain Tumor Associated with Epilepsy. ( 30783900 )
2019
20
HNRNPU: Key to Neurodevelopmental Disorders such as Intellectual Delay, Epilepsy, and Autism. ( 30800042 )
2019
21
Epilepsy and interictal epileptiform activity in patients with autism spectrum disorders. ( 30611007 )
2019
22
Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan. ( 30060984 )
2019
23
A Rasmussen encephalitis, autoimmune encephalitis, and mitochondrial disease mimicker: expanding the DNM1L-associated intractable epilepsy and encephalopathy phenotype. ( 30767894 )
2019
24
Epilepsy Emergencies: Status Epilepticus, Acute Repetitive Seizures, and Autoimmune Encephalitis. ( 30921018 )
2019
25
Spared cognitive and behavioral functions prior to epilepsy onset in a rat model of subcortical band heterotopia. ( 30689978 )
2019
26
Beta oscillations in the sensorimotor cortex correlate with disease and remission in benign epilepsy with centrotemporal spikes. ( 30790472 )
2019
27
Dysfunctional white-matter networks in medicated and unmedicated benign epilepsy with centrotemporal spikes. ( 30937973 )
2019
28
Electroencephalographic Resting-State Functional Connectivity of Benign Epilepsy with Centrotemporal Spikes. ( 30938108 )
2019
29
Concomitance of benign epilepsy with centrotemporal spikes and childhood absence epilepsy: an unusual case. ( 31011933 )
2019
30
A novel mutation in KCNQ3-related benign familial neonatal epilepsy: electroclinical features and neurodevelopmental outcome. ( 30782577 )
2019
31
Hyponatremia and metabolic bone disease in patients with epilepsy: A cross-sectional study. ( 30905745 )
2019
32
Pattern of Brain Injury Predicts Long-Term Epilepsy Following Neonatal Encephalopathy. ( 30642234 )
2019
33
Modelling traumatic brain injury and posttraumatic epilepsy in rodents. ( 30121231 )
2019
34
Affective, neurocognitive and psychosocial disorders associated with traumatic brain injury and post-traumatic epilepsy. ( 30059725 )
2019
35
"Breath holding spells" in a child with SCN8A-related epilepsy: Expanding the clinical spectrum. ( 30685519 )
2019
36
Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder. ( 30771550 )
2019
37
High rates of malnutrition and epilepsy: two common comorbidities in children with cerebral palsy ( 30761843 )
2019
38
Cerebrovascular disease burden in late-onset non-lesional focal epilepsy. ( 30776698 )
2019
39
Long-term prognosis of childhood absence epilepsy. ( 28325560 )
2019
40
Prevalence and demographic characteristics of comorbid epilepsy in children and adolescents with cerebral palsy: a nationwide population-based study. ( 30074083 )
2019
41
Seizure outcome and epilepsy patterns in patients with cerebral palsy. ( 30721873 )
2019
42
Long-term prognosis of epilepsy in patients with cerebral palsy. ( 30854645 )
2019
43
Risk factors associated with epilepsy development in children with cerebral palsy. ( 31011806 )
2019
44
Vaccination Status of Children With Epilepsy or Cerebral Palsy in Hunan Rural Area and a Relative KAP Survey of Vaccinators. ( 30984716 )
2019
45
Ictal Source Locations and Cortico-Thalamic Connectivity in Childhood Absence Epilepsy: Associations with Treatment Response. ( 30291582 )
2019
46
A Practical Guide to Treatment of Childhood Absence Epilepsy. ( 30734897 )
2019
47
Outgrowing seizures in Childhood Absence Epilepsy: time delays and bistability. ( 30737596 )
2019
48
Source localization of epileptiform discharges in childhood absence epilepsy using a distributed source model: a standardized, low-resolution, brain electromagnetic tomography (sLORETA) study. ( 30756246 )
2019
49
Historical trend toward improved long-term outcome in childhood absence epilepsy. ( 30856420 )
2019
50
A case of childhood absence epilepsy with focal spikes. ( 30880214 )
2019